rizatriptan benzoate NDC 68462-466

NDC codes

FDA NDC Directory

Product NDC (as listed)68462-466Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68462-0466Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68462-466-72	68462046672	12 POUCH in 1 CARTON (68462-466-72) / 1 BLISTER PACK in 1 POUCH / 1 TABLET in 1 BLISTER PACKMarketed from Dec 31, 2012
68462-466-99	68462046699	18 POUCH in 1 CARTON (68462-466-99) / 1 BLISTER PACK in 1 POUCH / 1 TABLET in 1 BLISTER PACKMarketed from Dec 31, 2012

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): rizatriptan benzoate
Generic name (nonproprietary): rizatriptan benzoate
Active ingredients: Rizatriptan benzoate — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Glenmark Pharmaceuticals Inc., USA
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 201967
Marketing start: Dec 31, 2012
Listing expires: Dec 31, 2026
Other FDA classes: Serotonin 1b Receptor Agonists (Mechanism)Serotonin 1d Receptor Agonists (Mechanism)
Identifiers: Product ID 68462-466_c7909d7b-34a6-42b0-ad12-eb25f3ce886eSPL ID c7909d7b-34a6-42b0-ad12-eb25f3ce886eSPL set ID 99c66300-bd75-4b31-9fab-88c6e4b12688RxCUI 312840, 314209UNII WR978S7QHHUPC 0368462465998, 0368462466995
Pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468462046672 followed by a unit qualifier and the quantity

Package 68462-0466-72. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 14, 2022.

Indications (excerpt from the label)

Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use • Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. • Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications ( 4 )]. • Rizatriptan benzoate tablets are not i…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 201967

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 201967
Product	Strength	Form · route	Labeler	Product NDC
rizatriptan benzoate	Rizatriptan benzoate 5 mg/1	TabletOral	Glenmark Pharmaceuticals Inc., USA	68462-465